- Home
- DGICB vs PVLA Comparison
DGICB vs PVLA Comparison
Compare DGICB & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- PVLA
- Stock Information
- Founded
- DGICB 1986
- PVLA 2015
- Country
- DGICB United States
- PVLA United States
- Employees
- DGICB N/A
- PVLA N/A
- Industry
- DGICB Property-Casualty Insurers
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- DGICB Finance
- PVLA Health Care
- Exchange
- DGICB Nasdaq
- PVLA Nasdaq
- Market Cap
- DGICB 562.0M
- PVLA 604.2M
- IPO Year
- DGICB N/A
- PVLA N/A
- Fundamental
- Price
- DGICB $15.33
- PVLA $76.84
- Analyst Decision
- DGICB
- PVLA Strong Buy
- Analyst Count
- DGICB 0
- PVLA 12
- Target Price
- DGICB N/A
- PVLA $68.67
- AVG Volume (30 Days)
- DGICB 838.0
- PVLA 182.0K
- Earning Date
- DGICB 10-30-2025
- PVLA 11-14-2025
- Dividend Yield
- DGICB 4.32%
- PVLA N/A
- EPS Growth
- DGICB 219.92
- PVLA N/A
- EPS
- DGICB 2.38
- PVLA N/A
- Revenue
- DGICB $987,826,050.00
- PVLA N/A
- Revenue This Year
- DGICB $2.26
- PVLA N/A
- Revenue Next Year
- DGICB $3.46
- PVLA N/A
- P/E Ratio
- DGICB $7.72
- PVLA N/A
- Revenue Growth
- DGICB 0.89
- PVLA N/A
- 52 Week Low
- DGICB $13.19
- PVLA $11.17
- 52 Week High
- DGICB $20.46
- PVLA $83.00
- Technical
- Relative Strength Index (RSI)
- DGICB 49.46
- PVLA 59.50
- Support Level
- DGICB $15.33
- PVLA $68.96
- Resistance Level
- DGICB $15.70
- PVLA $74.93
- Average True Range (ATR)
- DGICB 0.24
- PVLA 4.62
- MACD
- DGICB 0.08
- PVLA -0.23
- Stochastic Oscillator
- DGICB 33.78
- PVLA 56.13
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.